Disc Medicine Inc.
$ 68.85
0.78%
24 Apr - close price
- Market Cap 2,627,320,000 USD
- Current Price $ 68.85
- High / Low $ 69.92 / 67.11
- Stock P/E N/A
- Book Value 19.52
- EPS -6.01
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE -0.36 %
- 52 Week High 99.50
- 52 Week Low 40.00
About
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$100.17
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-19 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-08-11 | 2023-05-15 |
| Reported EPS | -1.64 | -1.77 | -1.58 | -1.02 | -0.98 | -0.8885 | -1.03 | -1.09 | -0.9 | -0.58 | -0.74 | -1.2 |
| Estimated EPS | -1.75 | -1.48 | -1.12 | -1.0738 | -1.1036 | -1.05 | -1.11 | -1 | -0.78 | -0.8 | -0.86 | -0.68 |
| Surprise | 0.11 | -0.29 | -0.46 | 0.0538 | 0.1236 | 0.1615 | 0.08 | -0.09 | -0.12 | 0.22 | 0.12 | -0.52 |
| Surprise Percentage | 6.2857% | -19.5946% | -41.0714% | 5.0102% | 11.1997% | 15.381% | 7.2072% | -9% | -15.3846% | 27.5% | 13.9535% | -76.4706% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.55 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IRON
2026-04-25 08:10:27
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter on February 13, 2026, regarding its bitopertin program, leading to a 22% stock price fall. The firm encourages investors to join a prospective class action seeking recovery of losses, citing its significant experience in securities class action litigation. Investors who purchased Disc Medicine securities may be entitled to compensation.
2026-04-25 06:10:27
Wall Street Zen has upgraded Disc Medicine (NASDAQ:IRON) from a "strong sell" to a "sell" rating, although the overall analyst consensus remains a "Moderate Buy" with an average price target of $104.80. The company recently reported quarterly EPS of ($1.62), beating estimates, but revenue of ($19.88) million missed expectations. Insider selling has also been noted, with CFO Jean M. Franchi and another insider selling shares totaling approximately $3.84 million in the last quarter.
2026-04-24 13:09:34
Disc Medicine (IRON) recently saw its Chief Medical Officer sell shares under a 10b5-1 plan, while its lead drug bitopertin is in a Phase 3 study. The company is also set to present new Phase 2 data for DISC-0974 at ASCO, which could enhance its investment narrative beyond a single-drug focus. Despite these developments, the company faces ongoing financial and regulatory risks, with its shares potentially overvalued according to some analyses.
2026-04-24 06:09:27
Twelve analysts have given Disc Medicine, Inc. (NASDAQ: IRON) a "Moderate Buy" consensus rating, with an average 12-month price target of $104.80. Despite insider sales and some analysts trimming price targets, the stock trades significantly below its consensus target and 1-year high. Hedge funds have also adjusted their holdings in the company.
2026-04-22 15:07:00
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin program, causing a 22% stock drop. Investors who suffered losses are encouraged to contact the firm to discuss joining a prospective class action lawsuit. The firm highlights its track record in securities class actions and invites affected shareholders to seek compensation.
2026-04-21 17:40:12
Disc Medicine's Chief Medical Officer, William Jacob Savage, sold 5,731 shares worth approximately $380,000, aligning with a pre-arranged 10b5-1 trading plan. This sale represents 6.73% of his direct holdings, leaving him with an estimated $5.44 million in company stock. The sale occurred amid a 70% increase in Disc Medicine's stock over the past year, while the company focuses on advancing its clinical-stage programs with substantial cash reserves.
